Central nervous system (CNS) metastases caused by non-small cell lung cancer (NSCLC) remain a frequent complication, and their occurrence has been altered little by cytotoxic chemotherapy.
Introduction
The development of central nervous system (CNS) metastases is a common and serious complication in non-small cell lung cancer (NSCLC), with an adverse impact on quality of life and survival (1) . Phase III trials of cytotoxic chemotherapy for stage IV NSCLC have commonly reported the frequency of brain metastases at the start of systemic therapy, but have seldom differentiated between CNS and non-CNS sites of disease progression during the trial (2, 3).
Conversely, the incidence of brain metastases has been widely reported in studies of patients with locally advanced NSCLC treated with definitive locoregional therapies. The addition of chemotherapy to chest irradiation and/or surgical resection in patients with stage III NSCLC has reduced extracranial distant relapses, but has had a limited impact on the frequency of brain metastases, with a 40% to 55% incidence of CNS failure after a median follow-up of 3 years (4, 5) . These and other data suggest that conventional chemotherapeutic agents may not cross the intact blood-brain barrier efficiently, leaving the brain relatively at risk for lung cancer relapse while other systemic sites are effectively treated by chemotherapy (6) . As systemic therapies for NSCLC continue to improve, prevention and control of brain metastases is likely to emerge as a more vital therapeutic strategy of overall disease control and improved quality of life.
Gefitinib and erlotinib are orally available, reversible inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) that have shown efficacy in patients with relapsed NSCLC and as initial therapy for patients with advanced NSCLC and sensitizing EGFR mutations (7, 8) . Prospective trials for patients with previously untreated, EGFR mutant advanced NSCLC have shown response rates of 55% to 75% and progression-free survival of 9 to 13 months for those given gefitinib or erlotinib, approximately two-fold greater than the results in similar patients treated with chemotherapy (7, (9) (10) (11) . These results have led to the Evidence from prospective reports has shown that gefitinib and erlotinib can cause regression of established brain metastases from NSCLC, with intracranial response rates reaching 75% in treatment-naïve NSCLC patients with mutated EGFR and synchronous brain metastases (14, 15) . These data suggest that in a molecularly selected population with brain metastases, gefitinib and erlotinib can achieve high response rates in metastatic brain tumors that have not traditionally been sensitive to conventional chemotherapeutic agents. However, there is incomplete data about the potential impact of EGFR-TKIs on the prevention and control of CNS metastases caused by NSCLC. A CNS-specific pharmacokinetic resistance as a result of poor CSF penetration of gefitinib and erlotinib in the absence of classical genetic mechanisms of acquired resistance to EGFR-TKIs (e.g. EGFR T790M) has been described; in published reports, the CSF-to-plasma concentration ratio of either gefitinib or erlotinib was less than 0.01, suggesting that the brain may be a susceptible site for progression of NSCLC targeted by EGFR inhibitors (16, 17) . However, our group recently reported on 100 patients with advanced NSCLC and somatic EGFR mutations initially treated with gefitinib or erlotinib, and found that the risk of developing CNS metastases and/or progression of pre-existing brain lesions was approximately 28% after a median potential follow-up of 42 months (18 multimodality approach (4, 5) . However, the contributing effects of EGFR-targeted therapy and tumor EGFR genotype on the risk of CNS progression remain undefined.
Screening for somatic mutations of EGFR has been performed for clinically selected NSCLC patients as part of routine care at our institution since 2004 (19) . Therefore, we retrieved information on the clinical presentation and course of our patients with advanced NSCLC and sensitizing EGFR mutations, comparing the risk of CNS progression in those initially treated with gefitinib or erlotinib to the risk in similar patients treated with chemotherapy. In particular, we sought to determine whether the apparent decrease in CNS metastases observed in EGFR mutant NSCLC patients treated with an EGFR-TKI was because treatment with gefitinib or erlotinib delays or effectively treats micrometastatic brain disease and, therefore, delays or prevents the development of CNS metastases.
Patients and Methods

Study design and patients
Patients were eligible for this study if they had stage IV NSCLC or stage I-IIIA NSCLC with systemic relapse and sensitizing EGFR mutations and were treated with either gefitinib, erlotinib or chemotherapy as their initial systemic therapy for advanced NSCLC (20) . Patients who had previously undergone definitive treatment for stage I-IIIA NSCLC that subsequently relapsed were included if surgery with curative intent had been performed, with or without preor postoperative radiation therapy and/or chemotherapy. Neoadjuvant or adjuvant chemotherapy or chemotherapy plus chest radiation therapy was allowed if completed more than 12 months prior to the start of systemic treatment for relapsed disease. Patients who were started on Patients were identified through a query of patient information for subjects prospectively enrolled in the Clinical Research Information System (CRIS) within the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute. This patient information has been used for previous reports (18, 21, 22) . One hundred and forty-two patients with sensitizing EGFR mutations were eligible for inclusion in this study; 73 of these patients have been studied and included in our prior publication on the rates of CNS progression in patients with EGFR mutant advanced NSCLC initially treated with a tyrosine kinase inhibitor of the EGFR (18) . One hundred and thirty-two additional patients who were initially treated with chemotherapy for advanced lung adenocarcinoma and who had not previously undergone EGFR mutation screening were identified. Of the 132 patients, 57 had adequate biopsy specimens available in the Department of Pathology at Brigham and Women's Hospital and were referred for EGFR sequencing to increase the number of EGFR mutant patients initially treated with chemotherapy.
Sensitizing mutations of EGFR were demonstrated in 5 of those 57 patients. Therefore, 147 patients from our institution were included in this analysis. Eight additional EGFR mutationpositive patients who had met all of the above eligibility criteria were reported by investigators from the Beth Israel Deaconess Medical Center, a member of the Dana-Farber/Harvard Cancer Center. Seven of these 8 patients have been studied and included in prior publications (18, 21, 23) . Thus, 155 patients were included in this analysis, which represent 62% of the 252 patients with somatic mutations of EGFR enrolled into both institutions' databases during the years of the study. Ninety-seven patients with EGFR mutant NSCLC were excluded from this analysis because of non-sensitizing EGFR mutations (defined later in this section, n=21); early-stage 
Mutation analysis
Tumor specimens were analyzed for the presence of somatic mutations of EGFR by Sanger dideoxy terminator sequencing of exons 18 to 21 according to previously described methods, with enhanced sensitivity for exon 19 and 21 mutations achieved by the use of specific peptide nucleic acid probes to inhibit amplification of wild-type sequence (24, 25) . For those samples (n = 4) that were deemed inadequate for conventional sequencing based on review by a molecular pathologist (N.L) and/or specimens with a low tumor content, SURVEYOR analysis was used as an alternate method of EGFR mutation detection, employing techniques that have been previously reported (26) . For the purposes of this study, the following EGFR mutations were considered sensitizing: deletions in exon 19, duplications in exon 19, deletion-insertions of exon 19, L858R point mutation, L861Q point mutation, and G719 missense point mutations (27) .
Statistical methods
Research. 
Results
Patient characteristics
Between v 61%; P = 0.04) and never-smokers (57% v 37%; P = 0.02) was higher in the EGFR-TKI group compared with the chemotherapy group. Most patients were White, non-Hispanic, although the EGFR-TKI group included a higher percentage of Asian patients (12% v 0%; P < 0.01). The majority of patients had stage IV disease at the time of initial diagnosis of NSCLC (84%) and adenocarcinoma histology (90%). Twenty-five patients had previously undergone definitive treatment for stage I-IIIA NSCLC that subsequently relapsed (16 patients with stage I, 4 with stage II, and 5 with stage IIIA) after a median of 41 months (range, 5 to 82 months). All patients had undergone resection with curative intent, and 7 of the 25 patients had been treated with neoadjuvant or adjuvant chemotherapy (n = 5) and/or radiation therapy (n = 6).
Twenty-four patients (24%) in the EGFR-TKI group and 12 patients (22%) in the chemotherapy group had brain metastases at the time of diagnosis of advanced NSCLC, before the initiation of first-line systemic therapy (P = 1.000). In the EGFR-TKI group, 20 of the 24 patients were treated with whole brain radiation therapy (WBRT) to doses of 3000 to 4050 cGy; two of the 20 patients were also treated with stereotactic radiosurgery (SRS) following WBRT.
One patient with three brain metastases was treated with SRS alone. Another patient underwent resection of a single brain metastasis followed by WBRT. In the chemotherapy group, six of 12 patients were treated with WBRT. A single brain metastasis was resected in 3 patients, followed by WBRT in 2 patients or SRS to the surgical cavity in one patient. Another patient with multiple brain metastases underwent resection of a symptomatic cerebellar mass followed by WBRT and SRS to residual lesions. The 4 remaining patients (EGFR-TKI: 2; chemotherapy: 2) had asymptomatic brain metastases measuring 6 mm or less and received no localized CNS therapy before their physicians elected to treat them with erlotinib (n = 2) or carboplatin plus paclitaxel (n = 2). Notably, seven of 12 patients (58%) in the chemotherapy group had a single 
brain metastasis on contrast-enhanced cranial MRI, compared with 3 of 24 patients (13%) in the EGFR-TKI group, explaining, at least in part, the larger proportion of patients who underwent surgical resection followed by postoperative radiation in the chemotherapy group. EGFR mutation data were available for all patients included in this analysis (Table 2) .
EGFR mutation analysis was performed on a pretreatment tissue specimen in 129 patients, whereas a rebiopsy specimen was tested in 15 patients following treatment with an EGFR-TKI.
A specimen date was not available in 11 patients. The proportions of classical mutations (deletions or deletion-insertions of exon 19, L858R point mutation) were similar between the two groups. All 8 patients with EGFR T790M had concurrent sensitizing EGFR mutations. Seven of the 8 patients had a clinical response to gefitinib (n = 2) or erlotinib (n = 5) for a median of 18 months (range, 10 to 33 months) before showing evidence of progressive disease that harbored both a sensitizing mutation and the resistant T790M mutation on repeat biopsy. Three of the 7 patients had initially been treated with chemotherapy for advanced NSCLC before receiving gefitinib (n = 1) or erlotinib (n = 2). A pretreatment tissue specimen from these 7 patients was either not available or contained insufficient tumor material for EGFR mutation analysis. In these 7 cases, the T790M mutation was presumed secondary and assumed not to be present before an EGFR-TKI was initiated. The remaining patient had de novo EGFR T790M without prior exposure to an EGFR-TKI or systemic chemotherapy. treatment with an EGFR-TKI did so before they had radiographic evidence of disease progression, after the identification of a sensitizing mutation of EGFR. Five patients were never treated with an EGFR-TKI. Of those 5 patients, two died shortly after the identification of a sensitizing EGFR mutation, before erlotinib could be initiated; another patient encountered delays in obtaining erlotinib because he was unable to secure second party support (insurance) in a timely fashion for purchase of the drug and passed away; and a sensitizing mutation of EGFR was retrospectively identified in 2 patients prompted by this study. The cumulative incidence curves of CNS progression for each group are shown in Figure   1 . The cumulative risk of CNS progression at 6, 12 and 24 months was 1%, 6% and 21%, respectively, in the EGFR-TKI group, and 7%, 19% and 32% in the chemotherapy group (P = 0.026, Figure 1A ). When the analysis was narrowed to only those 119 patients without preexisting brain metastases, the 6-, 12-and 24-month cumulative rates of CNS progression were 1%, 3% and 15% in the EGFR-TKI group, compared with corresponding rates of 7%, 17%, and 30% in the chemotherapy group (P = 0.032, Fig. 1B) . The time to the occurrence of CNS progression from the start of systemic treatment for advanced NSCLC was significantly longer in the EGFR-TKI group than in the chemotherapy group, with a median of 56.0 months versus 31.6 months (P = 0.010). The hazard ratio (HR) of CNS progression for upfront EGFR-TKI versus chemotherapy was 0.56 (95% CI, 0.34 to 0.94), suggesting a risk reduction of 40%. Because the cohort of patients initially treated with an EGFR-TKI was enriched for women and neversmokers compared with patients treated with upfront chemotherapy, we confirmed that the effect of upfront EGFR-TKI versus chemotherapy retained significance in a multivariate model that adjusted simultaneously for the impacts of gender, smoking history and prior CNS involvement (adjusted HR 0.52, 95% CI 0.32 to 0.87).
Patterns of disease progression
The overall survival did not differ significantly between the two treatment groups. The median survival times were 31.0 months for the EGFR-TKI group and 29.8 months for the chemotherapy group (P = 0.131; Fig. 2 ). The development of CNS progression was associated with a four to five-fold increase in the risk of death in both treatment groups (P < 0.001). The median survival after the diagnosis of CNS progression was 5.9 and 10.3 months in the EGFR-TKI and chemotherapy groups, respectively (P=0.608). 
Discussion
We retrospectively analyzed the impact of initial gefitinib or erlotinib therapy versus chemotherapy on the risk of CNS progression in patients with advanced NSCLC with mutated EGFR, and found a significantly lower cumulative risk of CNS progression in patients initially treated with a tyrosine kinase inhibitor of the EGFR compared with chemotherapy. The 6-, 12-, and 24-month cumulative risk of CNS progression was 1%, 6% and 21% for the EGFR-TKI group compared with 7%, 19% and 32% for the chemotherapy group (P = 0.026), and the cause specific HR for EGFR-TKI versus chemotherapy was 0.56 (95% CI, 0.34 to 0.94), suggesting a risk reduction of 40%. To our knowledge, this is the first retrospective study examining the impact of upfront EGFR-targeted therapy versus conventional chemotherapy on the risk of CNS progression in patients with sensitizing EGFR mutations, and it offers important insights into the management of this, and potentially other, molecularly defined subset(s) of NSCLC patients.
The introduction of agents directed against the EGFR has notably expanded the available therapeutic options for patients with advanced NSCLC. In the present study, we extend the data from our prior publication suggesting lower rates of CNS progression (compared with historical estimates) in EGFR mutant advanced NSCLC patients initially treated with gefitinib or erlotinib, and find that the observed lower frequency of CNS metastases seems to be due, at least in part, to the effect of the EGFR-TKI (18) . Notably, the lower cumulative rates of CNS progression in the EGFR-TKI group were largely related to a lower risk of CNS metastases in patients without prior CNS involvement (P = 0.032) and persisted despite high crossover (91%) to EGFRtargeted therapy in patients initially treated with chemotherapy. The time to the occurrence of CNS progression was also significantly prolonged in the EGFR-TKI group (56.0 v 31.6 months, P = 0.010), hinting at the potential of gefitinib and erlotinib at slowing the rate of development of 
CNS metastases from NSCLC. Whether gefitinib and erlotinib can penetrate into the CNS sufficiently to treat micrometastatic CNS disease from NSCLC and thereby prevent the outgrowth of CNS metastases, however, remains uncertain. Previous studies have demonstrated that CNS penetration of erlotinib and gefitinib at standard daily dosing is limited, and authors have suggested that incomplete drug penetration into the CNS may ultimately permit CNS failure in patients with NSCLC treated with gefitinib or erlotinib (17, 32) . Investigating the patterns of failure in patients with resected NSCLC and EGFR mutations undergoing adjuvant chemotherapy with or without an EGFR-TKI may help elucidate this issue. This approach would allow an evaluation of the limitations of primary therapy, and may help define subgroups of patients who perhaps should be treated differently because of a different natural history. Our observations also highlight the importance of elucidating the potential CNS efficacy of novel therapeutic agents. This may be of relevance for designing phase I trials of targeted therapy, because the paradigm has been shifting from establishing the maximum tolerated dose to establishing the optimal biological dose, which may not achieve adequate CNS concentrations (33) . The dosing schedule may also be pertinent, for example pulsatile versus continuous (16) .
The significance of EGFR mutations as a risk factor for CNS progression in NSCLC has not yet been clearly defined. In our study, the risk of CNS progression was not independently examined in a NSCLC cohort without EGFR mutations, thereby limiting our ability to evaluate a possible altered biological predisposition of EGFR mutated lung cancer for CNS sites. The significance of EGFR mutations on the outcome of CNS progression might be best evaluated in a study with an untreated control arm to distinguish therapeutic effect from underlying tumor biology. One such retrospective surgical series of 117 patients suggested that isolated recurrence in the brain following complete resection of the primary NSCLC was more frequent in patients 
with tumors bearing an EGFR mutation (mutated v wild-type EGFR, 24% v 9%; P = 0.15) after a median follow-up of 40 months (34) . Given the modest numbers, this did not reach statistical significance. Nonetheless, these data suggest that the lower rates of CNS progression in patients initially treated with an EGFR-TKI in our study might reflect an even more significant alteration in the potential course of disease for patients with EGFR mutations.
Our findings are limited to those of any retrospective analysis. Foremost, the observed frequency and patterns of CNS progression were subject to the frequency and thoroughness of clinical and radiographic evaluation. For example, asymptomatic CNS lesions were not specifically sought-after, and radiologic confirmation of clinical suspicion was necessary for the identification of CNS progression. However, in the absence of a systematic bias between the two treatment groups, our observations should be valid. Similarly, we could not evaluate an interaction between performance status and CNS progression due to the small number of patients with a performance status of 2 or more in both treatment groups (12 of 155, or 8%). Certainly, more prospective study of the topic of CNS progression with scheduled CNS imaging is warranted. Such study could also help define whether surveillance of the brain for early detection of CNS metastases could be useful in patients with EGFR mutant NSCLC. Tables   Table 1. Baseline patient characteristics   Table 2 . Epidermal growth factor receptor gene mutations identified 
